Our donor candidates undergo a strict protocol for their selection through different stages, which is under continuous revision and improvement. We introduce new screening tests and improve existing ones in order to offer the highest success rates for fullfulling a woman´s dream, not only of achieving motherhood but also having a healthy baby.

We do not only perform the tests required by Spanish law but complete the study according to recommendations of International Scientific Societies

  • 95 % of our donors are university students
  • 99% of donors are Spanish nationals.
  • Aged between 18 – 35 years old
  • Average age: 25 years old

Oocytes Donors Selection

An Individual and family medical history is carried out tracing back to grandparents, to rule out hereditary diseases, according to Spanish Law 9/2014 and RD 412/1996.

We add an evaluation the psychological history of the donor and his family environment as recommended by Spanish Society for Fertility (SEF).

Since the law does not address the exclusion criteria, we proceeded back in 2007 , with the help of various experts in each subject and in the context of Ceifer Classroom Training, to the publication of the book «THOUGHTS ON THE EVALUATION OF GAMETE AND EMBRYO DONORS«. This study provides support for the selection of donors.

  • A general physical examination is performed.
  • Cytology:
    • Tests for Chlamydia
    • Microbiological culture: enterobacteria, gardenerella, neissseria gonorrehoeae, urogenital mycoplasmas and fungi.

STD serology is initially performed at the donor selection stage, and is renewed quarterly when oocyte donations are made.

STDs Markers
HIV Ag p24, Ab 1+2
Hepatitis B HBsAg, HBsAb, HBcAb (IgM, IgG)
Hepatitis C Ab VHC IgM, IgG
Syphilis TPHA, VDRL
Herpes simplex type 1 Ab VHS I IgM
Herpes simplex type 2 Ab VHS II IgM
Cytomegalovirus (CMV) Ab CMV (IgG, IgM)

• PCR Analysis: HIV 1, HIV 2, Hepatitis B and Hepatitis C the day when follicule extraction takes place.

• Serum bank: we keep serum samples from the day when oocytes where extracted, to allow for a retrospective study measuring the levels of various biochemical markers at the moment of the oocytes extraction.

  • Blood type
  • Rh Factor
  • Blood count
  • Hemostasis:
    • Actividad Protrombina
    • TTPA
  • Biochemistry:
    • Glucose
    • Creatinine
    • Total cholesterol
    • HDL cholesterol
    • Triglycerides
    • Transaminases (GOT, GPT)

We have implemented a protocol for the study of genetic diseases at our sperm bank which is unique worldwide.

CEIFER Protocol for genetic studies allows discarding potential donors who are carriers of the most prevalent genetic diseases, specifically those of autosomal recessive nature that manifest only in the offspring.

Chromosome Study – Kariotype

Only donor candidates with normal kariotype are accepted. Additionally candidates with polymorphic karyotypes are discarded since they offer lower results for assisted reproduction techniques.

Carriers of autosomal recessive monogenic diseases

Genetic studies are carried out to eliminate donor candidates who are carriers of the most prevalent autosomal recessive monogenic diseases in our environment (Mediterranean area of Europe):

Disease Gene
Spinal Muscular AtrophySMN1
Cystic FibrosisCFTR
View Table 1*
X-chromosome linked diseases (57)Duchenne, Hemophilia A - B, Fabry, Pompe, G6PD, AR, mental retardation...*
View Table 2*

To reduce the risk of offspring affected by these and other diseases, it is recommended to perform Genetic Matching (more information below in DNA Bank and Genetic Matching)


From 2005 on CEIFER Biobanco has a sperm donor DNA bank. In this way, in case of genetic disease arising in the offspring, we can carry out the pertinent genetic studies.

CEIFER Biobanco thus has a global vision and the most advanced technology for:

  • Screening for genetic disorders in live birth cases where offspring is affected.
  • Implement screening tests for new genetic disorders in our screening protocols.


Genetic matching allows the genetic information from the donor woman to be compared with that of the male partner of the recipient woman in order to avoid the transmission of autosomal recessive genetic diseases.

To this end, a mass sequencing test against more than 307 genes related to monogenic recessive diseases is carried out. This analysis is performed using the most modern techniques of mass sequencing (Next Generation Sequencing – NGS).

Among these 307 genes screened there are variants with a particularly high incidence in the Mediterranean area. The results from our donor samples are compared with the similar genetic study performed on the recipient woman, selecting a suitable donor so that sperm donor and the receiving woman do not share mutations in the same genes.

(The genetic matching protocol does not eliminate the risk in the offspring of being affected or being a carrier of recessive diseases, even if it is one of the diseases studied. Its objective is the significant reduction of risks, depending on the disease object of study).


17-beta-hydroxysteroid dehydrogenase X deficiency HSD17B10
2-methylbutyrylglycinuria ACADSB
3-Methylcrotonyl-CoA carboxylase 1 deficiency MCCC1
3-Methylcrotonyl-CoA carboxylase 2 deficiency MCCC2
Aarskog-Scott syndrome, Mental retardation, X-linked syndromic 16 FGD1
Achondrogenesis Ib SLC26A2
Achromatopsia-3 CNGB3
Acyl-CoA dehydrogenase, medium chain, deficiency of ACADM
Acyl-CoA dehydrogenase, short-chain, deficiency of ACADS
Acyl-CoA dehydrogenase, short-chain, deficiency of CYP17A1
Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency CYP21A2
Adrenoleukodystrophy ABCD1
Alkaptonuria HGD
Allan-Herndon-Dudley syndrome SLC16A2
Alpha-methylacetoacetic aciduria ACAT1
Alpha-thalassemia/mental retardation syndrome ATRX
Alport syndrome, autosomal recessive, COL4A4 related
Anauxetic dysplasia RMRP
Androgen insensitivity AR
Argininemia ARG1
Argininosuccinic aciduria ASL
Arts Syndrome PRPS1
Aspartylglucosaminuria AGA
Ataxia with isolated vitamin E deficiency TTPA
Ataxia-telangiectasia ATM
Auditory neuropathy, autosomal recessive, 1 OTOF
Autoimmune polyendocrinopathy syndrome, type I, with or without reversible metaphyseal dysplasia AIRE
Autosomal Recessive Polycystic Kidney Disease (ARPKD) PKHD1
Bardet-Biedl syndrome 1 BBS1
Bardet-Biedl syndrome 10 BBS10
Bardet-Biedl syndrome 14, Joubert syndrome 5, Meckel syndrome 4, Senior-Loken syndrome 6 CEP290
Bardet-Biedl syndrome 2 BBS2
Bartter syndrome, type 4a BSND
Biotinidase deficiency BTD
Bjornstad syndrome BCS1L
Canavan disease ASPA
Carbamoylphosphate synthetase I deficiency CPS1
Carnitine deficiency, systemic primary SLC22A5
Carnitine-acylcarnitine translocase deficiency SLC25A20
Cerebral creatine deficiency syndrome 1 SLC6A8
Cerebrotendinous xanthomatosis CYP27A1
Ceroid lipofuscinosis, neuronal, 5 CLN5
Ceroid lipofuscinosis, neuronal, 8 CLN8
Ceroid lipofuscinosis, neuronal, 10 CTSD
Ceroid lipofuscinosis, neuronal, 3 CLN3
Ceroid lipofuscinosis, neuronal, 6, 601780 CLN6
Ceroid lipofuscinosis, neuronal, 7 MFSD8
Ceroid lipofuscinosis, neuronal, type 1 PPT1
Ceroid lipofuscinosis, neuronal, type 2 TPP1
Charcot-Marie-Tooth disease, type 4B1 MTMR2
Charcot-Marie-Tooth disease, type 4C SH3TC2
Charcot-Marie-Tooth disease, type 4D NDRG1
Charcot-Marie-Tooth Neuropathy Type 4A GDAP1
Cholestasis, benign recurrent intrahepatic, 2 ABCB11
Citrullinemia ASS1
Citrullinemia, neonatal-onset type II SLC25A13
Coffin-Lowry syndrome RPS6KA3
Combined malonic and methylmalonic acidemia ACSF3
Cone rod dystrophy 3 ABCA4
Cone-rod dystrophy, X-linked, 1 RPGR
Congenital disorder of glycosylation, type Ia PMM2
Corneal endothelial dystrophy and sensorineural deafness (CDPD) SLC4A11
CPT I (Carnitine Palmitoyltransferase IA) deficiency, hepatic, type IA CPT1A
CPT II (Carnitine Palmitoyltransferase) deficiency, lethal neonatal CPT2
CRASH/ MASA syndrome L1CAM
Cystathioninuria CTH
Cystic fibrosis, Congenital bilateral absence of vas deferens CFTR
Cystinosis, atypical nephropathic CTNS
Cystinuria SLC3A1
Cystinuria SLC7A9
Deafness, autosomal recessive 1A (DFNB1-related) GJB2
Deafness, autosomal recessive 12 CDH23
Deafness, autosomal recessive 18A USH1C
Deafness, autosomal recessive 23 PCDH15
Deafness, autosomal recessive 4, with enlarged vestibular aqueduct SLC26A4
Deafness, digenic GJB2/GJB3 GJB3
Dent disease 2 OCRL
Dihydrolipoamide dehydrogenase deficiency DLD
Duchenne muscular dystrophy, Becker muscular dystrophy DMD
Dysprothrombinemia, Prothrombin thrombophilia / Factor II deficiency F2
Ehlers-Danlos syndrome, type VI PLOD1
Ellis-van Creveld Syndrome EVC2
Emphysema due to Alpha1 Anti-Trypsin deficiency SERPINA1
Epidermolysis bullosa dystrophica, AR COL7A1
Epidermolysis bullosa, junctional, Herlitz type LAMB3
Epilepsy, X-linked, with variable learning disabilities and behavior disorders SYN1
Epileptic encephalopathy, early infantile, 1 ARX
Ethylmalonic encephalopathy ETHE1
Fabry disease GLA
Factor V Deficiency F5
Factor XI deficiency, autosomal recessive F11
Familial Mediterranean fever, autosomal recessive MEFV
Fanconi anemia FANCA
Fanconi anemia, complementation group C FANCC
Folate malabsorption, hereditary SLC46A1
Fragile X syndrome FMR1
Friedreich ataxia with retained reflexes FXN
Fructose intolerance ALDOB
Fumarase deficiency FH
G6PD deficiency / Favism G6PD
Galactokinase deficiency with cataracts GALK1
Galactose epimerase deficiency GALE
Galactosemia GALT
Gaucher disease, perinatal lethal GBA
Glutamate formiminotransferase deficiency FTCD
Glutaric acidemia IIA ETFA
Glutaric acidemia IIB ETFB
Glutaric acidemia IIC ETFDH
Glutaric aciduria, type I GCDH
Glycine encephalopathy AMT
Glycine encephalopathy GLDC
Glycogen storage disease Ia G6PC
Glycogen storage disease Ib SLC37A4
Glycogen storage disease II / Pompe disease GAA
Glycogen storage disease IIIa AGL
Glycogen storage disease IV GBE1
GM1-gangliosidosis, types I, II, III GLB1
Goldmann-Favre syndrome NR2E3
HARP syndrome PANK2
Hartnup disorder SLC6A19
Heimler syndrome, type 2 PEX6
Hemochromatosis, type 3 TFR2
Hemochromatosis: Type 2A: HFE2 Related HFE2
Hemophilia A, factor VIII deficiency, X-linked F8
Hemophilia B, factor IX deficiency F9
Herlitz Junctional Epidermolysis Bullosa: LAMC2 Related LAMC2
Histidinemia HAL
HMG-CoA lyase deficiency HMGCL
Holocarboxylase synthetase deficiency HLCS
Homocystinuria, B6-responsive and nonresponsive types CBS
Homocystinuria-megaloblastic anemia, cbl E type MTRR
Hypercholesterolemia, familial LDLR
Hypercholesterolemia, familial, autosomal recessive LDLRAP1
Hyperinsulinemic hypoglycemia, familial, type 2 KCNJ11
Hypermethioninemia due to adenosine kinase deficiency ADK
Hypermethioninemia due to Glycine N-methyltransferase deficiency GNMT
Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase AHCY
Hypermethioninemia, persistent, due to MAT1 deficiency MAT1A
Hyperoxaluria III HOGA1
Hyperoxaluria, primary, type I AGXT
Hyperoxaluria, primary, type II GRHPR
Hyperphenylalaninemia, BH4-deficient, A PTS
Hyperphenylalaninemia, BH4-deficient, C QDPR
Hyperphenylalaninemia, BH4-deficient, D PCBD1
Hyperprolinemia, type II ALDH4A1
Hypogonadotropic hypogonadism 7 without anosmia GNRHR
Hypothryoidism, congenital, nongoitrous 4 TSHB
Hypothyroidism, congenital, nongoitrous 1 TSHR
Ichthyosis, congenital, autosomal recessive 1 TGM1
Immunodeficiency, X-linked, with hyper-IgM CD40LG
Isovaleric acidemia IVD
Joubert syndrome 2 TMEM216
Joubert syndrome 4 NPHP1
Joubert syndrome 8 ARL13B
Joubert syndrome-3 AHI1
Krabbe disease GALC
LCHAD deficiency HADHA
Leber congenital amaurosis 13 RDH12
Leber congenital amaurosis 2 RPE65
Leber congenital amaurosis 8 CRB1
Leber congenital amaurosis-1 GUCY2D
Leber congenital amaurosis-4 AIPL1
Leigh syndrome, French-Canadian type LRPPRC
Leigh syndrome, due to COX deficiency SURF1
limb-girdle muscular dystrophy type 2B DYSF
Lipoid adrenal hyperplasia STAR
Lissencephaly, X-linked DCX
Macular corneal dystrophy CHST6
Malonyl-CoA decarboxylase deficiency, 248360 MLYCD
Mannosidosis, alpha-, types I and II MAN2B1
Maple syrup urine disease, type II DBT
Maple syrup urine disease, type IaBCKDHA
Maple syrup urine disease, type IbBCKDHB
McArdle disease / Glycogen Storage Disease: Type VPYGM
Meckel syndrome 1 MKS1
Mental retardation and microcephaly with pontine and cerebellar hypoplasia CASK
Mental retardation syndrome, X-linked, Siderius type PHF8
Mental retardation, X-linked OPHN1
Mental retardation, X-linked 1/78 IQSEC2
Mental retardation, X-linked 12/35 THOC2
Mental retardation, X-linked 21/34 IL1RAPL1
Mental retardation, X-linked 30/47 PAK3
Mental retardation, X-linked 41 GDI1
Mental retardation, X-linked 58 TSPAN7
Mental retardation, X-linked 63 ACSL4
Mental retardation, X-linked 9 FTSJ1
Mental retardation, X-linked 90 DLG3
Mental retardation, X-linked 94 GRIA3
Mental retardation, X-linked 97 ZNF711
Mental retardation, X-linked 99 USP9X
Mental retardation, X-linked syndromic 5 AP1S2
Mental retardation, X-linked syndromic, Raymond type ZDHHC9
Mental retardation, X-linked syndromic, Turner type HUWE1
Mental retardation, X-linked, Asperger syndrome susceptibility, X-linked NLGN4X
Mental retardation, X-linked, FRAXE type AFF2
Mental retardation, X-linked, syndromic 13 MECP2
Mental retardation, X-linked, syndromic 14 UPF3B
Mental retardation, X-linked, syndromic 15 CUL4B
Mental retardation, X-linked, syndromic, Claes-Jensen type KDM5C
Metachromatic leukodystrophy ARSA
Methylmalonic aciduria and homocystinuria, cblC type MMACHC
Methylmalonic aciduria and homocystinuria, cblD type MMADHC
Methylmalonic aciduria and homocystinuria, cblF type LMBRD1
Methylmalonic aciduria, vitamin B12-responsive, cbIB type MMAB
Methylmalonic aciduria, vitamin B12-responsive, cblA type MMAA
Methylmalonic aciduria, mut(0) type MUT
Methylmalonic and propionic acidemia and homocystinuria, cbIJ type ABCD4
Methylmalonyl-CoA epimerase deficiency MCEE
Mevalonic aciduria MVK
Microphthalmia, isolated 3 RAX
MTHFR Deficiency MTHFR
Mucolipidosis III alpha/beta, and type II GNPTAB
Mucolipidosis IV MCOLN1
Mucopolysaccharidosis Ih / Hurler Syndrome IDUA
Mucopolysaccharidosis II / Hunter Syndrome: X-linked IDS
Mucopolysaccharidosis IVA GALNS
Mucopolysaccharidosis type IIIA (Sanfilippo A) SGSH
Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 NAGLU
Mucopolysaccharidosis type IIIC (Sanfilippo C) HGSNAT
Mucopolysaccharidosis type IIID GNS
Mucopolysaccharidosis type VI (Maroteaux-Lamy) ARSB
Muscular dystrophy, limb-girdle, 2A CAPN3
Muscular dystrophy, limb-girdle, type 2D SGCA
Muscular dystrophy, limb-girdle, type 2E SGCB
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) POMGNT1
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 POMT1
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 POMT2
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5 FKRP
Myotonia congenita, dominant CLCN1
Nemaline myopathy 2, autosomal recessive NEB
Nephrotic syndrome, type 1 (Finnish Type) NPHS1
Neutropenia, severe congenital 3, autosomal recessive HAX1
Niemann-Pick disease, type A SMPD1
Niemann-Pick Disease, Type C2 NPC2
Niemann-Pick Disease: Type C1 NPC1
Nijmegen breakage syndrome NBN
Norrie disease NDP
Nystagmus 6, congenital, X-linked GPR143
Ornithine transcarbamylase deficiency OTC
Osteogenesis imperfecta, type VIII P3H1
Pelizaeus-Merzbacher disease, 312080 PLP1
Peroxisomal acyl-CoA oxidase deficiency ACOX1
Peroxisome biogenesis disorde 6A, Zellweger syndrome PEX10
Peroxisome biogenesis disorder 1A, Zellweger syndrome-1 PEX1
Phenylketonuria PAH
Phosphoglycerate kinase 1 deficiency PGK1
Pituitary hormone deficiency, combined, 2 PROP1
Primary ciliary dyskinesia DNAH5
Propionic acidemia PCCA
Propionic acidemiaPCCB
Pyruvate carboxylase deficiency PC
Pyruvate dehydrogenase E1-beta deficiency PDHB
Renpenning syndrome PQBP1
Retinitis pigmentosa 2 RP2
Retinitis pigmentosa 25 EYS
Retinitis pigmentosa 26 CERKL
Retinitis pigmentosa 39 USH2A
Retinitis pigmentosa 43 PDE6A
Retinitis pigmentosa 45 CNGB1
Retinitis pigmentosa 46 IDH3B
Retinitis pigmentosa 49 CNGA1
Retinitis pigmentosa 59 DHDDS
Retinoschisis: X-linked RS1
Rhizomelic chondrodysplasia punctata, type 1; Peroxisome biogenesis disorder PEX7
Rhizomelic chondrodysplasia punctata, type 3 AGPS
Sandhoff disease, infantile, juvenile, and adult forms HEXB
SCID, autosomal recessive, T-negative/B-positive type JAK3
Segawa syndrome, recessive (tyrosine hydroxylase deficiency) TH
Severe combined immunodeficiency due to ADA deficiency ADA
Severe combined immunodeficiency, X-linked IL2RG
Smith-Lemli-Opitz syndrome DHCR7
Spastic ataxia, Charlevoix-Saguenay type (ARSACS) SACS
Spastic paraplegia 11, autosomal recessive SPG11
Spastic paraplegia 7, autosomal recessive SPG7
Spinalmuscle atrophy (several types) SMN1
Tay-Sachs disease, GM2-gangliosidisus, several forms HEXA
Thalassemia, alpha- HBA1
Thalassemia, alpha-HBA2
Thalassemias, beta- (Sickle Cell Anemia) HBB
Thrombocytopenia, congenital amegakaryocytic MPL
Thryoid dyshormonogenesis 6 DUOX2
Thyroid dyshormonogenesis 1 SLC5A5
Thyroid dyshormonogenesis 2A TPO
Thyroid dyshormonogenesis 3 TG
Thyroid dyshormonogenesis 4 IYD
Thyroid dyshormonogenesis 5 DUOXA2
Thyroid hormone resistance THRB
Treacher Collins syndrome 3 POLR1C
Trifunctional protein deficiency HADHB
Tyrosinemia, type I FAH
Tyrosinemia, type II TAT
Usher syndrome, type 1B; Deafness, autosomal dominant 11MYO7A
Usher syndrome, type 1G USH1G
Usher syndrome, type 2D / Deafness, autosomal recessive 31 WHRN
Usher syndrome, type 3A CLRN1
Ventricular tachycardia, catecholaminergic polymorphic, 2 CASQ2
Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 TRDN
VLCAD deficiency ACADVL
Walker-Warburg syndrome (congenital with brain and eye anomalies) FKTN
Wilson disease ATP7B
Wolman disease (lysosomal acid lipase deficiency) LIPA
X-linked mental retardation (XLMR) associated with macrocephaly BRWD3
X-linked mixed deafness with perilymphatic gusher POU3F4


We use Kitasato vitrification medium, approved by the competent authority (CE label) for use with human specimens.

  • This allows us to meet the highest recommendations issued by international organizations related to banks of human tissues and cells (EU Directive 2004/23/EC and Law 9/2014).
  • We ensure the traceability of the process, allowing at any time to know the batch and obtaining information to identify the problem.
  • Ensures sterility of our vitrification process.
Our vitrification protocol makes use of CryoTop® Method, approved by the competent authority (EU label) for use in human specimens.
CryoTop® vitrification method is highly effective for oocytes and embryos cryopreservation providing:
  • Excelent survival rate for oocytes.
  • Fertilization.
  • Embryonic development (optimum cleavage-stage results).
  • Pregnancy.

Vitrification containers are identified with a UNIQUE CODE that incorporates a serial code and donor identification number. This allows for traceability of each container with vitrified oocytes.

  • Identification of every container with the donor identification  code to prevent confusion between containers from different donors.
  • Imposibility for external manipulation of the code, as it is not possible to remove without destruction of the label.
  • Easy identification by the receiving Reproductive Center.
CEIFER BIOBANCO offers to reproduction centers several options for requesting vitrified oocytes.

  • OVOPACK 6: 6 vitrified MII oocytes
  • OVOPACK 8: 8 vitrified MII oocytes
  • OVOPACK 10: 10 vitrified MII oocytes
  • OVOPACK 12: 12 vitrified MII oocytes
More Info

Containers holding oocytes are stored inside containers filled with liquid nitrogen, temperature regulated at -196 °C.

  • Immersion into liquid nitrogen is the best method for human oocyte and ovarian tissue cryopreservation.
  • Our containers are 24h monitored for temperature and filling levels.


We only use approved certified containers. Liquid nitrogen travels absorbed into porous material.

  • Approved for shipping biological samples
  • Approved for transport on land, by ship and air freight shipping
  • Extra security with no risk of spillage during transportation


  • Transportation containers are shipped conveniently protected inside security packaging specifically designed for CEIFER Biobanco.
  • The strength of this packaging system provides additional safety unique in our sector, reducing tear and deterioration of samples during transportation.
  • It makes possible to implement our anti tampering system for transportation.


  • The system uses a numbered loop seal, fit to the locking system.
  • The identification number of the clip is unique and must match the number of the shipping report.

Our delivery system makes possible to have a sample available at destination within 24h.

Since 1993 we do all sample transportation through the courier company MRW. This gives us preferential treatment, allowing to resolve quickly the problems inherent to urgent transportation.

  • There is specific tracking of our shipments throughout the transportation process.
  • More than 20 years with no records of theft guarantee the chain of custody.
  • To check all services please go to ‘Order oocytes’.